ReviewDrugs & aging2010
Multiple sclerosis in the elderly patient.
Review in Drugs & aging, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed.
- Adult-onset and late-onset multiple sclerosis in older adults in a Finnish university hospital.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2026Article
- Comorbidity and modifiable risk factors in multiple sclerosis.Therapeutic advances in neurological disorders · 2026Review
- From youth to late age: a comparative analysis of clinical and demographic profiles in multiple sclerosis by age at onset.Postepy psychiatrii neurologii · 2025Article
- Impact of discontinuing disease-modifying therapies on health care utilization among midlife patients with multiple sclerosis in the United States.Journal of managed care & specialty pharmacy · 2024Article
- Review of evidence linking exposure to environmental stressors and associated alterations in the dynamics of immunosenescence (ISC) with the global increase in multiple sclerosis (MS).Immunity & ageing : I & A · 2024Review
- IL-6 Inhibition as a Therapeutic Target in Aged Experimental Autoimmune Encephalomyelitis.International journal of molecular sciences · 2024Article
- Multiple sclerosis in the elderly: a retrospective cohort study.Journal of neurology · 2024Article
- Case report: Primary cytomegalovirus infection in a patient with late onset multiple sclerosis treated with dimethyl fumarate.Frontiers in neurology · 2024Article
- A continuum of languishing to flourishing: exploring experiences of psychological resilience in multiple sclerosis family caregivers.International journal of qualitative studies on health and well-being · 2022Article
- Diagnostic Cerebrospinal Fluid Biomarker in Early and Late Onset Multiple Sclerosis.Biomedicines · 2022Article
- Accumulation of pTreg cells is detrimental in late-onset (aged) mouse model of multiple sclerosis.Aging cell · 2022Article
- Disease-Modifying Drug Uptake and Health Service Use in the Ageing MS Population.Frontiers in immunology · 2021Article
- Review
- Informing Medication Discontinuation Decisions among Older Adults with Relapsing-Onset Multiple Sclerosis.Drugs & aging · 2020Article
- Cancer Risk and Multiple Sclerosis: Evidence From a Large Italian Cohort.Frontiers in neurology · 2019Article
- Cognition in older patients with multiple sclerosis compared to patients with amnestic mild cognitive impairment and healthy older adults.Neuropsychology · 2018Article
- Feasibility study design and methods for a home-based, square-stepping exercise program among older adults with multiple sclerosis: The SSE-MS project.Contemporary clinical trials communications · 2017Article
- Levels and Rates of Physical Activity in Older Adults with Multiple Sclerosis.Aging and disease · 2016Article
- Is Time to Reach EDSS 6.0 Faster in Patients with Late-Onset versus Young-Onset Multiple Sclerosis?PloS one · 2016Article
- Humoral Responses to Diverse Autoimmune Disease-Associated Antigens in Multiple Sclerosis.PloS one · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Multiple sclerosis (MS) is an acquired inflammatory demyelinating disease of the CNS that is typically diagnosed in the second or third decade of life. It is generally believed that over the last few decades the life expectancy of patients with adult onset MS (AOMS) has approached that of the general population as a result of better medical and nursing care. Thus, an increasing number of MS patients are entering or have reached senescence. A second group of elderly patients with MS that may be very different in terms of disease pathogenesis are patients with late onset MS (LOMS). The diagnosis in LOMS patients can be challenging because of a large number of age-associated MS differential diagnoses, atypical presentations, a low index of suspicion and the lack of diagnostic criteria specific to this age group. Also, specific problems these patients encounter have only recently become a focus of attention. Changes in renal and hepatic function with age, in addition to the coexistence of medical co-morbidities, require special attention in the management of elderly patients with MS. In this review we outline the characteristics of senescent AOMS and LOMS patients. In addition, we discuss therapeutic strategies in elderly patients with MS based on our knowledge of immunosenescence and age-associated characteristics of this disorder. Given the overall aging of the population, focusing on these two patient groups appears highly relevant.
Indexed as
Identifiers
20359260What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.